Target intelligence / Profile preview

Melanoma cell adhesion molecule (MCAM) (MCAM)

Target
MCAM
Molecular classification
Cell adhesion molecule, Immunoglobulin superfamily, Receptor
01

Overview

Melanoma cell adhesion molecule (MCAM), also widely known as CD146 or MUC18, is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It is primarily expressed on endothelial cells, smooth muscle cells, pericytes, and a subset of activated T lymphocytes, where it plays a critical role in cell-cell adhesion, endothelial junction cohesion, and vascular permeability. MCAM also functions as a signaling receptor, triggering intracellular cascades such as tyrosine phosphorylation of FYN and FAK1, which link cell surface adhesion to cytoskeletal rearrangement and cell migration.\n\nIn pathological states, MCAM is highly overexpressed in various solid tumors, including melanoma, osteosarcoma, and lung, breast, and ovarian cancers, where it promotes tumor angiogenesis, epithelial-mesenchymal transition (EMT), and metastatic dissemination. Consequently, MCAM has emerged as a promising therapeutic target in oncology and inflammatory diseases. Therapeutic strategies targeting MCAM include antibody-drug conjugates (ADCs) like AMT-253, which delivers a topoisomerase I inhibitor payload to tumor cells, and monoclonal antibodies like imaprelimab (PRX003) designed to block its pro-inflammatory and angiogenic signaling. Additionally, dual-targeting CAR-T cell therapies directed against MCAM are under clinical evaluation. However, because MCAM is also expressed on normal vasculature, managing on-target, off-tumor toxicities remains a key therapeutic challenge.

Other names
CD146MUC18MelCAMMETCAMHEMCAMS-endo 1 endothelial-associated antigenGicerinCell surface glycoprotein MUC18Melanoma-associated antigen MUC18Melanoma-associated antigen A32Cell surface glycoprotein P1H12
02

Mechanism of action

Antibody-drug conjugate targeting MUC18/CD146 to deliver a cytotoxic payload (exatecan) to tumor cells; monoclonal antibody blocking CD146-mediated cell adhesion and signaling; CAR-T cell therapy targeting CD146-expressing tumor cells

03

Biological functions

Cell adhesionAngiogenesisCell migrationSignal transductionEpithelial-mesenchymal transitionVascular permeabilityImmune response
04

Disease associations

CancerInflammationAutoimmune diseaseCardiovascular diseaseMultiple sclerosisPsoriasis
05

Safety considerations

On-target off-tumor toxicity due to expression on normal vascular endothelium and smooth muscle cellsCytokine release syndrome (CRS) or neurotoxicity with CAR-T therapiesInfusion-related reactionsPotential vascular permeability or bleeding issues due to its role in endothelial junction cohesion
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

CD146 expressionMUC18 expressionSoluble CD146 (sCD146) levels in plasma

Beyond the preview

Go deeper on Melanoma cell adhesion molecule (MCAM) (MCAM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Melanoma cell adhesion molecule (MCAM) (MCAM).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call